🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Addus HomeCare Corporation ADUS R2KR3KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.addus.com
Company Profile ↓
$121.81
+4.71% 1Y
Mkt Cap$2.27B
P/E21.33
P/B1.82
52W High$122.75
52W Low$88.49
Book Value$62.77
EPS (TTM)$5.71

Company Overview

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. Its Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. Its Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company serves federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 24.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 17.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 21.3, below the sector median of 25.4.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.42B (+23.2% YoY); net profit $95.91M.
  • Trailing 12 Months Year-on-year growth — revenue +8.0%, earnings +24.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 17.2%, profit CAGR 24.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:17.15%
1 Year:8.00%

Compounded Profit Growth

5 Years:24.46%
1 Year:24.20%

Stock Price Performance

1 Year:+4.71%
6 Months:+27.27%
3 Months:+5.33%
1 Month:+6.80%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 97% of range
$88.49 $122.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.93 · Neutral
Price Performance
1M+6.80%
3M+5.33%
6M+27.27%
1Y+4.71%
Valuation vs Sector

P/E of 21.33 is below the sector median of 25.45 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 17.2% over 5 years.
  • Profit CAGR of 24.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
21.33
Industry PE
25.45
Forward P/E
16.15
PEG Ratio
0.99
Book Value
$62.77
Price to Book
1.82
P/S
1.45
EV/EBITDA
12.96
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
17.15%
Profit 5Y
24.46%
Revenue (YoY)
8.00%
Earnings (YoY)
24.20%

Profitability & Returns

ROCE
10.76%
ROE
9.71%
ROA
6.27%
Profit Margin
7.13%
Op Margin
9.68%
Gross Margin
31.98%
EPS (Latest Qtr)
$1.49
EPS (TTM)
$5.71

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
1.46
Current Ratio
1.69
Debt
$108.82M
Total Assets
$1.46B
Current Assets
$272.88M
Working Capital
$120.00M

Ownership

Promoter Holding
2.81%
Chg in Prom Hold
-0.00%
FII / Inst Holding
107.91%
Chg in FII Hold
-0.20%

Financial Snapshot

Enterprise Value
$2.27B
Total Revenue (TTM)
$1.48B
EBITDA
$160.54M
Free Cash Flow
$116.25M
Operating Cash Flow
$162.40M
Shares Outstanding
18.66M
Gross Margin
31.98%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADUS Addus HomeCare Corporation R2KR3KPHARMA 121.81 21.33 $2.27B 0.00% 10.76% 9.71% 17.15% 24.46%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------101.67M103.63M108.66M112.03M109.13M130.89M137.34M139.29M138.51M148.91M168.99M192.38M190.22M184.58M193.99M196.00M205.30M217.89M216.66M226.63M236.94M240.50M251.60M259.98M270.72M280.75M286.92M289.79M337.71M349.44M362.30M373.08M363.61M377.42M
Cost of Revenue ----------------------------------230.03M235.57M245.59M249.47M247.74M-
Gross Profit 23.52M22.19M24.32M25.70M27.42M28.66M27.39M28.58M29.12M30.79M27.58M35.38M36.41M37.43M36.83M39.69M45.18M57.54M55.84M55.00M56.30M59.10M61.20M68.81M67.05M70.19M75.60M75.19M78.42M82.32M86.73M88.18M93.16M92.20M107.68M113.88M116.72M123.61M115.87M121.56M
Operating Expenses ----------------------------------77.16M80.99M83.78M81.33M81.80M-
Operating Income 4.28M3.02M653.00K4.39M2.50M7.69M7.03M5.99M5.88M7.47M4.24M6.55M5.61M6.43M5.50M7.39M7.33M14.53M10.66M9.61M12.52M11.72M12.17M17.05M17.36M13.51M16.89M17.52M18.61M21.54M22.84M23.64M26.18M25.95M30.51M32.89M32.94M42.28M34.07M38.94M
EBITDA ----------------------------------34.96M37.38M38.10M47.02M38.61M-
Interest Expense ----------------------------------4.02M3.52M3.34M2.73M2.15M-
Pretax Income ----------------------------------27.00M29.95M30.35M40.15M32.43M-
Tax Provision ----------------------------------5.77M7.89M7.51M10.37M7.36M-
Net Income 2.89M3.32M157.00K2.60M1.70M7.57M4.31M2.76M3.46M3.15M4.63M4.05M3.36M4.39M4.30M5.29M4.91M10.74M8.66M6.91M9.12M8.45M8.89M11.60M11.58M8.47M11.25M11.54M12.68M14.85M15.41M15.83M18.08M20.16M21.23M22.05M22.85M29.78M25.07M27.61M
Diluted EPS 0.260.290.010.230.150.660.370.240.290.270.400.340.270.330.320.390.350.680.540.430.570.530.550.720.720.530.700.710.780.910.950.971.101.101.151.201.241.611.341.49

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------400.93M425.99M516.65M648.79M764.77M-951.12M1.06B1.15B1.42B
Cost of Revenue -------------651.38M718.77M779.58M960.66M
Gross Profit 76.61M59.72M61.47M64.05M67.74M83.73M91.32M106.34M115.88M136.80M179.24M226.24M-299.74M339.88M375.02M461.87M
Operating Expenses -------------231.00M248.92M272.33M323.26M
Operating Income 11.78M9.27M12.92M15.66M15.46M18.07M16.02M15.48M25.25M22.83M34.75M44.51M-68.74M90.96M102.69M138.62M
EBITDA -------------83.14M106.56M120.61M157.47M
Interest Expense -------------8.91M11.11M7.73M13.61M
Pretax Income -------------60.17M81.33M99.35M127.44M
Tax Provision -------------14.15M18.81M25.75M31.54M
Net Income 3.60M6.03M-1.98M7.63M19.14M12.24M11.62M12.16M11.95M16.43M25.24M33.13M-46.02M62.52M73.60M95.91M
Diluted EPS ---0.180.711.731.101.041.071.031.331.772.08-2.843.834.065.18

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --166.92M154.69M149.86M163.93M180.80M185.80M229.86M271.69M348.09M636.75M892.58M-937.99M1.02B1.41B1.44B
Current Assets --------------222.81M200.00M260.38M269.49M
Cash & Equivalents 6.11M518.00K816.00K2.02M1.74M15.56M13.36M4.10M8.01M53.75M70.41M111.71M145.08M-79.96M64.79M98.91M81.62M
Inventory ------------------
Receivables --------------125.50M115.50M122.88M151.69M
Total Liabilities --78.83M68.25M55.44M50.08M52.85M44.07M72.10M95.38M79.60M161.16M373.91M-304.45M317.73M442.14M352.00M
Current Liabilities --37.13M43.29M39.19M45.54M43.20M42.19M49.62M55.08M61.50M87.53M143.90M-131.15M145.12M155.87M149.49M
Long Term Debt --40.03M24.96M16.25M--1.88M22.48M39.86M17.22M59.16M193.90M-131.77M124.13M218.44M120.96M
Total Debt --------------178.05M175.18M273.13M171.36M
Total Equity 34.58M80.57M88.09M86.44M94.42M113.86M126.79M141.58M154.67M170.34M268.49M475.59M518.68M-633.54M706.69M970.49M1.09B
Shares Outstanding --------------16.13M16.23M18.15M18.52M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.93M10.70M15.95M15.40M27.39M-4.11M-743.00K52.77M33.20M12.02M109.41M-105.11M112.25M116.43M111.51M
Investing Cash Flow -14.85M-6.20M-1.05M-619.00K2.89M--10.72M-21.74M-24.27M-67.79M-188.70M-214.24M--106.59M-119.24M-354.61M-32.50M
Financing Cash Flow 18.18M-4.21M-13.69M-15.07M-16.46M--2.64M26.39M17.24M51.24M217.99M138.19M--87.45M-8.18M272.30M-96.30M
Capital Expenditure -671.00K-612.00K-551.00K-1.11M-887.00K-5.27M-2.21M-1.71M-3.62M-5.35M-4.62M-6.83M--8.30M-9.45M-6.05M-7.72M
Free Cash Flow -9.60M10.09M15.40M14.29M26.51M-1.89M-2.46M49.16M27.85M7.40M102.58M-96.81M102.79M110.38M103.79M
Net Change in Cash --------------88.93M-15.17M34.12M-17.29M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------26.5%27.2%26.5%27.6%29.6%-31.5%32.1%32.5%32.5%
Operating Margin % -------3.9%5.9%4.4%5.4%5.8%-7.2%8.6%8.9%9.7%
Net Margin % -------3.0%2.8%3.2%3.9%4.3%-4.8%5.9%6.4%6.7%
ROE % 4.5%6.8%-2.3%8.1%16.8%9.7%8.2%7.9%7.0%6.1%5.3%6.4%-7.3%8.8%7.6%8.8%
ROCE % -7.1%11.6%14.2%13.1%13.1%11.2%8.6%11.7%8.0%6.3%5.9%-8.5%10.3%8.2%10.8%

Shareholding Pattern

Insiders
2.81%
Institutions
107.91%
Public Float
111.03%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 18.34% 3.43M $391.63M
2 Capital Research Global Investors 7.44% 1.39M $158.91M
3 Dimensional Fund Advisors LP 4.47% 835.16K $95.48M
4 Vanguard Capital Management LLC 4.23% 789.33K $90.24M
5 State Street Corporation 4.17% 777.83K $88.93M
6 Silvercrest Asset Management Group, LLC 3.70% 691.25K $79.03M
7 Wasatch Advisors LP 3.65% 680.93K $77.85M
8 American Century Companies Inc 3.02% 564.64K $64.55M
9 Geode Capital Management, LLC 2.76% 515.52K $58.94M
10 Principal Financial Group, Inc. 2.20% 411.56K $47.05M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADUS

Yahoo Finance ue, 13 Oct 2026

Addus HomeCare Announces Third Quarter 2026 Earnings Release and Conference Call

FRISCO, Texas, October 13, 2026--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release earnings for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026, after …

Yahoo Finance Mon, 28 Sep 2026

2 Safe-and-Steady Stocks with Exciting Potential and 1 That Underwhelm

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Yahoo Finance Wed, 23 Sep 2026

Can Addus HomeCare (ADUS) Compound Wealth at Scale?

When examining a long-term compounder, astute market participants look past quarterly headlines to evaluate core operational drivers, margin stability, and pricing power. Addus HomeCare (NASDAQ:ADUS) embodies many classic characteristics of…

Yahoo Finance Wed, 16 Sep 2026

Addus HomeCare (ADUS) Heads To Jefferies, Is It Still 13% Undervalued?

Addus HomeCare (ADUS) heads into its 2026 Jefferies Healthcare Services and Technology Conference appearance with fresh attention on its AccentCare personal care acquisition and the stock’s recent sector driven move. After a strong run that…

Yahoo Finance ue, 15 Sep 2026

Addus HomeCare's Acquisition of AccentCare's Personal Care Business Likely to Support Growth, UBS Says

Addus HomeCare' (ADUS) $275 million acquisition of AccentCare's personal care division will likely s

Yahoo Finance Mon, 14 Sep 2026

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta

ADUS — Frequently Asked Questions

What is the current share price of Addus HomeCare Corporation (ADUS)?

As of 2026-10-23 16:27 PDT, Addus HomeCare Corporation (ADUS) trades at $121.81 on NasdaqGS. Its 52-week range is $88.49 to $122.75.

What is the market capitalisation of ADUS?

Addus HomeCare Corporation (ADUS) has a market capitalisation of $2.27B on NasdaqGS.

What is the P/E ratio of ADUS?

ADUS trades at a trailing price-to-earnings (P/E) ratio of 21.33. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.82.

What is the return on equity (ROE) of ADUS?

ADUS has a return on equity (ROE) of 9.71%. Its return on capital employed (ROCE) is 10.76%.

Is ADUS a good stock to buy?

This page provides a data-driven analysis of Addus HomeCare Corporation (ADUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space